Ontology highlight
ABSTRACT:
SUBMITTER: Plock N
PROVIDER: S-EPMC5421726 | biostudies-literature | 2017 May
REPOSITORIES: biostudies-literature
Plock N N Vollert S S Mayer M M Hanauer G G Lahu G G
Clinical and translational science 20170115 3
TAK-648 is a PDE4 inhibitor with demonstrated preclinical antidiabetic properties. Our objective was to develop a translational pharmacokinetic/pharmacodynamic (PK/PD) model for human type 2 diabetes (T2D) dose prediction using HbA<sub>1c</sub> results from a db/db mouse study. Estimated parameters in combination with tPDE4i values calculated for the clinical roflumilast dose of 500 μg were used to translate preclinical effects of TAK-648 to required exposure in humans. A first-in-human study wi ...[more]